Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma

William R. Wikoff, Dmitry Grapov, Johannes F. Fahrmann, Brian DeFelice, William N. Rom, Harvey I. Pass, Kyoungmi Kim, UyenThao T. Nguyen, Sandra L. Taylor, David R. Gandara, Karen Kelly, Oliver Fiehn, Suzanne Miyamoto

Research output: Contribution to journalArticle

41 Scopus citations

Abstract

Adenocarcinoma, a type of non-small cell lung cancer, is the most frequently diagnosed lung cancer and the leading cause of lung cancer mortality in the United States. It is well documented that biochemical changes occur early in the transition from normal to cancer cells, but the extent to which these alterations affect tumorigenesis in adenocarcinoma remains largely unknown. Herein, we describe the application of mass spectrometry and multivariate statistical analysis in one of the largest biomarker research studies to date aimed at distinguishing metabolic differences between malignant and nonmalignant lung tissue. Gas chromatography time-of-flight mass spectrometry was used to measure 462 metabolites in 39 malignant and nonmalignant lung tissue pairs from current or former smokers with early stage (stage IA-IB) adenocarcinoma. Statistical mixed effects models, orthogonal partial least squares discriminant analysis and network integration, were used to identify key cancer-associated metabolic perturbations in adenocarcinoma compared with nonmalignant tissue. Cancer-associated biochemical alterations were characterized by (i) decreased glucose levels, consistent with the Warburg effect, (ii) changes in cellular redox status highlighted by elevations in cysteine and antioxidants, alpha- and gamma-tocopherol, (iii) elevations in nucleotide metabolites 5,6-dihydrouracil and xanthine suggestive of increased dihydropyrimidine dehydrogenase and xanthine oxidoreductase activity, (iv) increased 5'-deoxy-5'-methylthioadenosine levels indicative of reduced purine salvage and increased de novo purine synthesis, and (v) coordinated elevations in glutamate and UDP-N-acetylglucosamine suggesting increased protein glycosylation. The present study revealed distinct metabolic perturbations associated with early stage lung adenocarcinoma, which may provide candidate molecular targets for personalizing therapeutic interventions and treatment efficacy monitoring.

Original languageEnglish (US)
Pages (from-to)410-418
Number of pages9
JournalCancer Prevention Research
Volume8
Issue number5
DOIs
StatePublished - May 1 2015

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma'. Together they form a unique fingerprint.

  • Cite this

    Wikoff, W. R., Grapov, D., Fahrmann, J. F., DeFelice, B., Rom, W. N., Pass, H. I., Kim, K., Nguyen, U. T., Taylor, S. L., Gandara, D. R., Kelly, K., Fiehn, O., & Miyamoto, S. (2015). Metabolomic markers of altered nucleotide metabolism in early stage adenocarcinoma. Cancer Prevention Research, 8(5), 410-418. https://doi.org/10.1158/1940-6207.CAPR-14-0329